Table 4.
Rifampicin (n = 37) | No-rifampicin (n = 31) | P | |
---|---|---|---|
AST, n (%) | |||
≤1.5 Upper limit of normal | 4 (10.8) | 5 (16.1) | 0.722 |
≤2.0 Upper limit of normal | 1 (2.7) | 1 (3.2) | 1.0 |
>2.0 Upper limit of normal | 2 (5.4) | 0 (0) | 0.496 |
ALT, n (%) | |||
≤1.5 Upper limit of normal | 1 (2.7) | 0 (0) | >0.99 |
≤2.0 Upper limit of normal | 1 (2.7) | 6 (19.4) | 0.041 |
>2.0 Upper limit of normal | 8 (21.6) | 1 (3.2) | 0.033 |
eGFR, n (%) | |||
≤60 mL/min | 2 (5.4) | 1 (3.2) | >0.99 |
≤30 mL/min | 0 (0) | 0 (0) | >0.99 |
≤15 mL/min | 0 (0) | 0 (0) | >0.99 |
Therapeutic regimen for BD, n (%) | |||
Glucocorticoids | 17 (45.9) | 11 (35.5) | 0.462 |
Immunosuppressants | 37 (100) | 31 (100) | – |
Biological agents | 4 (10.8) | 6 (19.4) | 0.494 |
Incomplete rifampicin treatment | 5 (13.5) | 0 (0) | >0.99 |
BD, Behçet’s disease; LTBI, latent tuberculosis infection; CNS, central nervous system; AST, aspartate transaminase; ALT, alanine transaminase; eGFR, estimated glomerular filtration rate. P < 0.05 was considered statistically significant were shown in bold.